BeiGene Ltd. (06160.HK): The clinical study of Sutokira in the treatment of patients with mantle cell lymphoma has achieved positive results.

Wisdom Financial APP News, BeiGene (06160.HK) announced that on August 29, 2025, the company announced positive results from the Phase 1/2 clinical study (BGB-11417-201) of its new generation and potentially best-in-class BCL2 inhibitor, Sutokra, for the treatment of mantle cell lymphoma (MCL) adult patients who have previously received Bruton's tyrosine kinase (BTK) inhibitors and anti-CD20 therapy. The company plans to release the full data at an upcoming academic conference.